Envafolimab
Cancer immunotherapy medication
- L01FF05 (WHO)
- 2102192-68-5
- 381609252
- DB15769
- ES1M06M6QH
Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy.[1] It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours.[2] Envafolimab (KN035) has obtained the U.S. FDA's orphan drug designation for advanced biliary tract cancer.
References
- v
- t
- e